{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:19:55Z","timestamp":1787008795238,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kidney Research United Kingdom","award":["TF_002_20230627"],"award-info":[{"award-number":["TF_002_20230627"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is increasing in prevalence and is associated with substantial morbidity and mortality. Early initiation of cardiorenal protective medications is recommended to improve outcomes. Barriers to implementation include renal function monitoring and resources to initiate and titrate treatment. We aimed to evaluate the feasibility and acceptability of a protocolled point-of-care testing (POCT) pathway to optimise people living with proteinuric CKD in primary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A pilot quality improvement study conducted across three general practices in Greater London, United Kingdom. Inclusion criteria were adults (18\u201380 years) with hypertension and\/or type 2 diabetes mellitus, proteinuria, and reduced kidney function (eGFR 30\u201375\u2005ml\/min\/1.73m2), who were identified using electronic health records. POCT for creatinine and potassium enabled real-time decision-making using a traffic light clinical decision support system. The primary outcome was recruitment rate and patient acceptability. Secondary efficacy outcomes included medication optimisation and renal function changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-five (52%) of 48 patients agreed to participate. Overall, 23\/25 (92%) completed the pathway and 20\/25 (80%) achieved pharmacological optimisation. There were no significant adverse events. POCT was successful in 44\/57 (77%) of cases and well tolerated by most participants (10\/13; 77%). Patient satisfaction was high (12\/13; 92%), with most preferring advanced nurse practitioners or pharmacists in future clinics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A POCT-led CKD optimisation pathway is feasible and well-accepted in primary care. While high medication optimisation rates were achieved, barriers to recruitment and engagement remain. Future studies should evaluate scalability, long-term clinical impact, and cost-effectiveness to inform wider implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/fampra\/cmaf083","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:56:20Z","timestamp":1760183780000},"source":"Crossref","is-referenced-by-count":2,"title":["A pilot point-of-care kidney disease clinic in primary care to pharmacologically optimise people with chronic kidney disease (PROTECT KIDNEY)"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0292-7582","authenticated-orcid":false,"given":"Rouvick Mariano","family":"Gama","sequence":"first","affiliation":[{"name":"Department of Inflammation Biology, Faculty of Life Sciences and Medicine, King's College London , London SE5 9NU ,","place":["United Kingdom"]},{"name":"King's Kidney Care, King's College Hospital, King's College Hospital NHS Foundation Trust , London SE5 9RS ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Griffiths","sequence":"additional","affiliation":[{"name":"King's Kidney Care, King's College Hospital, King's College Hospital NHS Foundation Trust , London SE5 9RS ,","place":["United Kingdom"]},{"name":"Department of Women and Children\u2019 Health, Faculty of Life Sciences and Medicine, King's College London , London SE5 9RJ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Beencke","sequence":"additional","affiliation":[{"name":"Department of Long-Term Conditions, Health Innovation Network South London , London SE1 7EU ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Dalrymple","sequence":"additional","affiliation":[{"name":"Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London , London SE1 9NH ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mitchell","sequence":"additional","affiliation":[{"name":"King's Kidney Care, King's College Hospital, King's College Hospital NHS Foundation Trust , London SE5 9RS ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prema","family":"Ravi","sequence":"additional","affiliation":[{"name":"Chelsfield Surgery, Orpington Primary Care Network , Orpington BR6 6HD, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mayhew","sequence":"additional","affiliation":[{"name":"Department of Long-Term Conditions, Clinical Effectiveness South East London (CESEL) , South East London ICS, 160 Tooley Street, London SE1 2TZ, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9485-4645","authenticated-orcid":false,"given":"Sharlene","family":"Greenwood","sequence":"additional","affiliation":[{"name":"King's Kidney Care, King's College Hospital, King's College Hospital NHS Foundation Trust , London SE5 9RS ,","place":["United Kingdom"]},{"name":"King's Kidney Rehab Team, King's College Hospital, King's College Hospital NHS Foundation Trust , London SE5 9RS ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Bramham","sequence":"additional","affiliation":[{"name":"King's Kidney Care, King's College Hospital, King's College Hospital NHS Foundation Trust , London SE5 9RS ,","place":["United Kingdom"]},{"name":"Department of Women and Children\u2019 Health and Centre for Nephrology, Urology and Transplantation, Faculty of Life Sciences and Medicine, King's College London , London SE5 9RJ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2025103008110749800_cmaf083-B1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2025103008110749800_cmaf083-B2","author":"Kidney Research UK"},{"key":"2025103008110749800_cmaf083-B3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the dDapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2025103008110749800_cmaf083-B4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-Kidney Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2025103008110749800_cmaf083-B5","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2025103008110749800_cmaf083-B6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025103008110749800_cmaf083-B7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2025103008110749800_cmaf083-B8","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.34067\/KID.0001172021","article-title":"eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined","volume":"2","author":"Meraz-Mu\u00f1oz","year":"2021","journal-title":"Kidney360"},{"key":"2025103008110749800_cmaf083-B9","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2025103008110749800_cmaf083-B10","author":"National Institute for Health and Care Excellence"},{"key":"2025103008110749800_cmaf083-B11","author":"National Institute for Health and Care Excellence"},{"key":"2025103008110749800_cmaf083-B12","author":"National Institute for Health and Care Excellence"},{"key":"2025103008110749800_cmaf083-B13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12916-024-03555-0","article-title":"Chronic kidney disease: detect, diagnose, disclose\u2014a UK primary care perspective of barriers and enablers to effective kidney care","volume":"22","author":"Stewart","year":"2024","journal-title":"BMC Med"},{"key":"2025103008110749800_cmaf083-B14","author":"Gbinigie"},{"key":"2025103008110749800_cmaf083-B15","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1093\/pch\/pxy013","article-title":"Screening for kidney disease in iIndigenous Canadian children: tThe FINISHED screen, triage and treat program","volume":"23","author":"Dart","year":"2018","journal-title":"Paediatr Child Health"},{"key":"2025103008110749800_cmaf083-B16","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1038\/ki.2009.538","article-title":"Screening for chronic kidney disease in Australia: a pilot study in the community and workplace","volume":"77","author":"Mathew","year":"2010","journal-title":"Kidney Int Suppl"},{"key":"2025103008110749800_cmaf083-B17","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1515\/cclm-2014-0932","article-title":"Application of a point of care creatinine device for trend monitoring in kidney transplant patients: fit for purpose?","volume":"53","author":"van Lint","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"2025103008110749800_cmaf083-B18","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.ekir.2023.03.003","article-title":"Patient self-testing of kidney function at home, a prospective clinical feasibility study in kidney transplant recipients","volume":"8","author":"Murray","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025103008110749800_cmaf083-B19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/jcpt.12081","article-title":"Feasibility of point-of-care creatinine testing in community pharmacy to monitor drug therapy in ambulatory elderly patients","volume":"38","author":"Geerts","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"2025103008110749800_cmaf083-B20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/1715163520902495","article-title":"Community pharmacist identification of chronic kidney disease using point-of-care technology: a pilot study","volume":"153","author":"Donovan","year":"2020","journal-title":"Can Pharm J (Ott)"},{"key":"2025103008110749800_cmaf083-B21","doi-asserted-by":"publisher","first-page":"i125","DOI":"10.1093\/ndt\/gfac069.011","article-title":"MO378: the importance of community pharmacy in chronic kidney disease patient management. Drug dosage adjustment and nephrotoxicity detection","volume":"37","author":"C\u00e1mara Ramos","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2025103008110749800_cmaf083-B22","doi-asserted-by":"publisher","first-page":"7284","DOI":"10.1038\/s41598-024-56765-0","article-title":"Community pharmacist-led point-of-care eGFR screening: early detection of chronic kidney disease in high-risk patients","volume":"14","author":"Jairoun","year":"2024","journal-title":"Sci Rep"},{"key":"2025103008110749800_cmaf083-B23","doi-asserted-by":"publisher","first-page":"n2061","DOI":"10.1136\/bmj.n2061","article-title":"A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance","volume":"374","author":"Skivington","year":"2021","journal-title":"BMJ"},{"key":"2025103008110749800_cmaf083-B24","author":"APL Clinical Effectiveness Group"},{"key":"2025103008110749800_cmaf083-B25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.47176\/mjiri.35.27","article-title":"Clinical decision support systems-based interventions to improve medication outcomes: a systematic literature review on features and effects","volume":"35","author":"Shahmoradi","year":"2021","journal-title":"Med J Islam Repub Iran"},{"key":"2025103008110749800_cmaf083-B26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.34067\/KID.0000000000000374","article-title":"Mortality, health care burden, and treatment of CKD: a multinational, observational study (OPTIMISE-CKD)","volume":"5","author":"Tangri","year":"2024","journal-title":"Kidney360"},{"key":"2025103008110749800_cmaf083-B27","doi-asserted-by":"publisher","first-page":"e033428","DOI":"10.1136\/bmjopen-2019-033428","article-title":"Point-of-care blood tests during home visits by out-of-hours primary care clinicians; a mixed methods evaluation of a service improvement","volume":"10","author":"Hayward","year":"2020","journal-title":"BMJ Open"},{"key":"2025103008110749800_cmaf083-B28","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1017\/S1463423622000238","article-title":"Advancing multimorbidity management in primary care: a narrative review","volume":"23","author":"Aramrat","year":"2022","journal-title":"Prim Health Care Res Dev"},{"key":"2025103008110749800_cmaf083-B29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12875-024-02406-4","article-title":"Sustainable solutions to barriers of point-of-care diagnostic testing services in health facilities without laboratories in the Bono Region, Ghana: a qualitative study","volume":"25","author":"Ansu-Mensah","year":"2024","journal-title":"BMC Prim Care"},{"key":"2025103008110749800_cmaf083-B30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/bios10100133","article-title":"Point of care diagnostics in resource-limited settings: a review of the present and future of PoC in its most needed environment","volume":"10","author":"Heidt","year":"2020","journal-title":"Biosensors (Basel)"},{"key":"2025103008110749800_cmaf083-B31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s40814-023-01416-w","article-title":"A review of sample sizes for UK pilot and feasibility studies on the ISRCTN registry from 2013 to 2020","volume":"9","author":"Totton","year":"2023","journal-title":"Pilot Feasibility Stud"}],"container-title":["Family Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/42\/6\/cmaf083\/65039694\/cmaf083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/42\/6\/cmaf083\/65039694\/cmaf083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:11:24Z","timestamp":1761826284000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/fampra\/article\/doi\/10.1093\/fampra\/cmaf083\/8306569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10,21]]}},"URL":"https:\/\/doi.org\/10.1093\/fampra\/cmaf083","relation":{},"ISSN":["0263-2136","1460-2229"],"issn-type":[{"value":"0263-2136","type":"print"},{"value":"1460-2229","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,21]]},"article-number":"cmaf083"}}